PEG-IFN alfa-2a

DRUG5 trials

Conditions

Advanced Squamous Cell CarcinomaChronic Hepatitis C (CHC)Cutaneous Squamous Cell CarcinomaHepatitis B, ChronicHepatitis C, ChronicSquamous Cell Carcinoma

Phase 1

Cemiplimab/Peg-Interferon-α in Advanced CSCC

WithdrawnNCT05729139

Baptist Health South FloridaAdvanced Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma

Start: 2023-07-31End: 2028-07-31Updated: 2023-08-09

Phase 3

Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C

CompletedNCT01753557

Tanabe Pharma CorporationChronic Hepatitis C (CHC)

Start: 2012-12-31End: 2014-11-30Updated: 2026-01-06

Phase 4

A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection

CompletedNCT00192647

Hoffmann-La RocheHepatitis C, Chronic

Start: 2004-08-31End: 2009-03-31Updated: 2016-08-04

Unknown Phase

An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C

CompletedNCT01447446

Hoffmann-La RocheHepatitis C, Chronic

Start: 2011-09-30End: 2015-07-31Updated: 2017-03-30

A Study to Collect Blood Biomarker Samples From Participants With Chronic Hepatitis B (CHB) Who Received Treatment With Pegasys (Peginterferon Alfa-2a) ± Nucleoside/Nucleotide Analogue

CompletedNCT01855997

Hoffmann-La RocheHepatitis B, Chronic

Start: 2013-08-20End: 2014-11-28Updated: 2017-04-05

Related Papers

Genetic variation in <i>FCER1A</i> predicts peginterferon alfa‐2a‐induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B

Journal of Viral Hepatitis2019-04-125 citations